225 related articles for article (PubMed ID: 33818823)
21. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients.
Mattioli F; Fucile C; Del Bono V; Marini V; Parisini A; Molin A; Zuccoli ML; Milano G; Danesi R; Marchese A; Polillo M; Viscoli C; Pelosi P; Martelli A; Di Paolo A
Eur J Clin Pharmacol; 2016 Jul; 72(7):839-48. PubMed ID: 27048201
[TBL] [Abstract][Full Text] [Related]
22. Population Pharmacokinetic Model and Dosing Simulation of Meropenem Using Measured Creatinine Clearance for Patients with Sepsis.
Fukumoto S; Ohbayashi M; Okada A; Kohyama N; Tamatsukuri T; Inoue H; Kato A; Kotani T; Sagara H; Dohi K; Kogo M
Ther Drug Monit; 2023 Jun; 45(3):392-399. PubMed ID: 36253888
[TBL] [Abstract][Full Text] [Related]
23. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy.
Isla A; Rodríguez-Gascón A; Trocóniz IF; Bueno L; Solinís MA; Maynar J; Sánchez-Izquierdo JA; Pedraz JL
Clin Pharmacokinet; 2008; 47(3):173-80. PubMed ID: 18307371
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetics of fluconazole in critically ill patients receiving extracorporeal membrane oxygenation and continuous renal replacement therapy: an ASAP ECMO study.
Novy E; Abdul-Aziz MH; Cheng V; Burrows F; Buscher H; Corley A; Diehl A; Gilder E; Levkovich BJ; McGuinness S; Ordonez J; Parke R; Parker S; Pellegrino V; Reynolds C; Rudham S; Wallis SC; Welch SA; Fraser JF; Shekar K; Roberts JA
Antimicrob Agents Chemother; 2024 Jan; 68(1):e0120123. PubMed ID: 38063399
[TBL] [Abstract][Full Text] [Related]
25. The Effect of Renal Replacement Therapy and Antibiotic Dose on Antibiotic Concentrations in Critically Ill Patients: Data From the Multinational Sampling Antibiotics in Renal Replacement Therapy Study.
Roberts JA; Joynt GM; Lee A; Choi G; Bellomo R; Kanji S; Mudaliar MY; Peake SL; Stephens D; Taccone FS; Ulldemolins M; Valkonen MM; Agbeve J; Baptista JP; Bekos V; Boidin C; Brinkmann A; Buizen L; Castro P; Cole CL; Creteur J; De Waele JJ; Deans R; Eastwood GM; Escobar L; Gomersall C; Gresham R; Jamal JA; Kluge S; König C; Koulouras VP; Lassig-Smith M; Laterre PF; Lei K; Leung P; Lefrant JY; Llauradó-Serra M; Martin-Loeches I; Mat Nor MB; Ostermann M; Parker SL; Rello J; Roberts DM; Roberts MS; Richards B; Rodríguez A; Roehr AC; Roger C; Seoane L; Sinnollareddy M; Sousa E; Soy D; Spring A; Starr T; Thomas J; Turnidge J; Wallis SC; Williams T; Wittebole X; Zikou XT; Paul SK; Lipman J;
Clin Infect Dis; 2021 Apr; 72(8):1369-1378. PubMed ID: 32150603
[TBL] [Abstract][Full Text] [Related]
26. Meropenem pharmacokinetics during extracorporeal membrane oxygenation and continuous haemodialysis: a case report.
Saito J; Shoji K; Oho Y; Aoki S; Matsumoto S; Yoshida M; Nakamura H; Kaneko Y; Hayashi T; Yamatani A; Capparelli E; Miyairi I
J Glob Antimicrob Resist; 2020 Sep; 22():651-655. PubMed ID: 32417590
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics and Pharmacodynamics of Extended Infusion Versus Short Infusion Piperacillin-Tazobactam in Critically Ill Patients Undergoing CRRT.
Shotwell MS; Nesbitt R; Madonia PN; Gould ER; Connor MJ; Salem C; Aduroja OA; Amde M; Groszek JJ; Wei P; Taylor ME; Tolwani AJ; Fissell WH
Clin J Am Soc Nephrol; 2016 Aug; 11(8):1377-1383. PubMed ID: 27197907
[TBL] [Abstract][Full Text] [Related]
28. Optimized Dosing Regimens of Meropenem in Septic Children Receiving Extracorporeal Life Support.
Wang Y; Chen W; Huang Y; Wang G; Li Z; Yan G; Chen C; Lu G
Front Pharmacol; 2021; 12():699191. PubMed ID: 34504424
[No Abstract] [Full Text] [Related]
29. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration.
Giles LJ; Jennings AC; Thomson AH; Creed G; Beale RJ; McLuckie A
Crit Care Med; 2000 Mar; 28(3):632-7. PubMed ID: 10752806
[TBL] [Abstract][Full Text] [Related]
30. Exploring population pharmacokinetic models in patients treated with vancomycin during continuous venovenous haemodiafiltration (CVVHDF).
Kirwan M; Munshi R; O'Keeffe H; Judge C; Coyle M; Deasy E; Kelly YP; Lavin PJ; Donnelly M; D'Arcy DM
Crit Care; 2021 Dec; 25(1):443. PubMed ID: 34930430
[TBL] [Abstract][Full Text] [Related]
31. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.
Ehmann L; Zoller M; Minichmayr IK; Scharf C; Maier B; Schmitt MV; Hartung N; Huisinga W; Vogeser M; Frey L; Zander J; Kloft C
Crit Care; 2017 Oct; 21(1):263. PubMed ID: 29058601
[TBL] [Abstract][Full Text] [Related]
32. Levetiracetam dosing in patients receiving continuous renal replacement therapy.
Chaijamorn W; Charoensareerat T; Rungkitwattanakul D; Phunpon S; Sathienluckana T; Srisawat N; Pattharachayakul S
Epilepsia; 2021 Sep; 62(9):2151-2158. PubMed ID: 34247386
[TBL] [Abstract][Full Text] [Related]
33. Population pharmacokinetics and simulations of imipenem in critically ill patients undergoing continuous renal replacement therapy.
Li S; Xie F
Int J Antimicrob Agents; 2019 Jan; 53(1):98-105. PubMed ID: 30626495
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy.
Wenzler E; Butler D; Tan X; Katsube T; Wajima T
Clin Pharmacokinet; 2022 Apr; 61(4):539-552. PubMed ID: 34792787
[TBL] [Abstract][Full Text] [Related]
35. Systematic Evaluation of Pharmacokinetic Models for Model-Informed Precision Dosing of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy.
Schatz LM; Brinkmann A; Röhr A; Frey O; Greppmair S; Weinelt F; Zoller M; Scharf C; Hempel G; Liebchen U
Antimicrob Agents Chemother; 2023 May; 67(5):e0010423. PubMed ID: 37125925
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of meropenem in children with sepsis undergoing extracorporeal life support: A prospective observational study.
Wang Y; Li Z; Chen W; Yan G; Wang G; Lu G; Chen C
J Clin Pharm Ther; 2021 Jun; 46(3):754-761. PubMed ID: 33476064
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic Drug Monitoring of Antibiotic Drugs in Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis: A Critical Review.
Matusik E; Boidin C; Friggeri A; Richard JC; Bitker L; Roberts JA; Goutelle S
Ther Drug Monit; 2022 Feb; 44(1):86-102. PubMed ID: 34772891
[TBL] [Abstract][Full Text] [Related]
38. Meropenem Target Attainment and Population Pharmacokinetics in Critically Ill Septic Patients with Preserved or Increased Renal Function.
Gijsen M; Elkayal O; Annaert P; Van Daele R; Meersseman P; Debaveye Y; Wauters J; Dreesen E; Spriet I
Infect Drug Resist; 2022; 15():53-62. PubMed ID: 35035223
[TBL] [Abstract][Full Text] [Related]
39. Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.
Burger R; Guidi M; Calpini V; Lamoth F; Decosterd L; Robatel C; Buclin T; Csajka C; Marchetti O
J Antimicrob Chemother; 2018 Dec; 73(12):3413-3422. PubMed ID: 30304491
[TBL] [Abstract][Full Text] [Related]
40. Cefepime Population Pharmacokinetics and Target Attainment in Critically Ill Patients on Continuous Renal Replacement Therapy.
Al-Shaer MH; Philpott CD; Droege CA; Courter JD; Healy DP; Droege ME; Ernst NE; Mueller EW; Peloquin CA
Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33722885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
